Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.52 USD | -3.47% | +5.84% | -24.04% |
May. 08 | Tango Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 04 | British billionaire Joe Lewis fined $5 million by US judge for insider trading | RE |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | - | 957.8 | 639.3 | 1,010 | 803.5 | - | - |
Enterprise Value (EV) 1 | - | 816.5 | 579.3 | 943.3 | 839.2 | 567.3 | 478.9 |
P/E ratio | -2.53 x | -11.6 x | -5.89 x | -9.17 x | -5.56 x | -5.31 x | -4.68 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | 25.9 x | 25.7 x | 27.6 x | 25.7 x | 24.7 x | 24.2 x |
EV / Revenue | - | 22 x | 23.3 x | 25.8 x | 26.8 x | 17.4 x | 14.4 x |
EV / EBITDA | - | -14.3 x | -5.29 x | -8.44 x | -5.07 x | -2.89 x | -2.16 x |
EV / FCF | - | - | - | -7.89 x | -6.13 x | -4.05 x | -3.08 x |
FCF Yield | - | - | - | -12.7% | -16.3% | -24.7% | -32.5% |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | - | 87,546 | 88,177 | 101,990 | 106,846 | - | - |
Reference price 2 | 11.44 | 10.94 | 7.250 | 9.900 | 7.520 | 7.520 | 7.520 |
Announcement Date | 4/20/21 | 3/28/22 | 3/27/23 | 3/18/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | 37.04 | 24.86 | 36.53 | 31.31 | 32.59 | 33.26 |
EBITDA 1 | - | -57.29 | -109.5 | -111.8 | -165.4 | -196.5 | -222 |
EBIT 1 | - | -58.19 | -111.1 | -114.2 | -158.2 | -175.1 | -200.8 |
Operating Margin | - | -157.09% | -446.79% | -312.57% | -505.36% | -537.34% | -603.79% |
Earnings before Tax (EBT) 1 | - | -57.94 | -108.1 | -101.6 | -146.1 | -162.8 | -182.3 |
Net income 1 | -51.97 | -58.24 | -108.2 | -101.7 | -147.6 | -166.5 | -194.4 |
Net margin | - | -157.21% | -435.14% | -278.54% | -471.6% | -510.77% | -584.59% |
EPS 2 | -4.530 | -0.9400 | -1.230 | -1.080 | -1.353 | -1.416 | -1.606 |
Free Cash Flow 1 | - | - | - | -119.5 | -137 | -140 | -155.5 |
FCF margin | - | - | - | -327.18% | -437.62% | -429.59% | -467.56% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 4/20/21 | 3/28/22 | 3/27/23 | 3/18/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 5.716 | 5.758 | 5.771 | 6.92 | 6.411 | 5.766 | 14.6 | 10.73 | 5.431 | 6.471 | 8.198 | 8.028 | 8.597 | 7.588 | 7.588 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -21.98 | -25.38 | -25.2 | -29.92 | -30.57 | -30.29 | -23.25 | -25.63 | -35.01 | -42.26 | -38.41 | -40.13 | -39.65 | -40.7 | -41.39 |
Operating Margin | -384.6% | -440.76% | -436.7% | -432.41% | -476.79% | -525.25% | -159.25% | -238.78% | -644.69% | -652.99% | -468.47% | -499.91% | -461.22% | -536.43% | -545.53% |
Earnings before Tax (EBT) 1 | -21.87 | -25.21 | -24.86 | -29.05 | -29.01 | -28.01 | -20.65 | -22.24 | -30.72 | -37.87 | -35.46 | -36.71 | -36.81 | -39.21 | -40.05 |
Net income 1 | -22.05 | -25.21 | -24.86 | -29.05 | -29.06 | -28.01 | -20.71 | -22.26 | -30.76 | -37.91 | -35.94 | -36.98 | -37.21 | -39.21 | -40.05 |
Net margin | -385.69% | -437.79% | -430.74% | -419.8% | -453.28% | -485.74% | -141.87% | -207.45% | -566.43% | -585.91% | -438.41% | -460.67% | -432.83% | -516.76% | -527.9% |
EPS 2 | -0.2600 | -0.2900 | -0.2800 | -0.3300 | -0.3300 | -0.3200 | -0.2300 | -0.2300 | -0.3000 | -0.3500 | -0.3343 | -0.3343 | -0.3329 | -0.3600 | -0.3675 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/28/22 | 5/11/22 | 8/10/22 | 11/10/22 | 3/27/23 | 5/9/23 | 8/7/23 | 11/8/23 | 3/18/24 | 5/8/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | 35.8 | - | - |
Net Cash position 1 | - | 141 | 60 | 66.4 | - | 236 | 325 |
Leverage (Debt/EBITDA) | - | - | - | - | -0.2161 x | - | - |
Free Cash Flow 1 | - | - | - | -120 | -137 | -140 | -156 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | - | 7.69 | 1.53 | 3.65 | 4.2 | 5.1 |
Capex / Sales | - | - | 30.94% | 4.18% | 11.66% | 12.89% | 15.33% |
Announcement Date | 4/20/21 | 3/28/22 | 3/27/23 | 3/18/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.04% | 803M | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- TNGX Stock
- Financials Tango Therapeutics, Inc.